• The global Adalimumab Injection market was valued at US$ 1872.7 million in 2023 and is projected to reach US$ 2698.8 million by 2030, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
• The global key manufacturers of Adalimumab Injection include AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd. and Hisun Biopharmaceutical, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
• This report aims to provide a comprehensive presentation of the global market for Adalimumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Injection. This report contains market size and forecasts of Adalimumab Injection in global, including the following market information:
• We surveyed the Adalimumab Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Email: help@24marketresearch.com
Call: 1(332) 2424 294 (Int'l)
